DAB2IP predicts treatment response and prognosis of ESCC patients and modulates its radiosensitivity through enhancing IR-induced activation of the ASK1-JNK pathway.

Abstract

BACKGROUND:

Disabled homolog 2 interacting protein (DAB2IP) plays a tumor-suppressive role in several types of human cancers. However, the molecular status and function of the DAB2IP gene in esophageal squamous cell carcinoma (ESCC) patients who received definitive chemoradiotherapy is rarely reported.

METHODS:

We examined the expression dynamics of DAB2IP by immunohistochemistry (IHC) in 140 ESCC patients treated with definitive chemoradiotherapy. A series of in vivo and in vitro experiments were performed to elucidate the effect of DAB2IP on the chemoradiotherapy (CRT) response and its underlying mechanisms in ESCC.

RESULTS:

Decreased expression of DAB2IP in ESCCs correlated positively with ESCC resistance to CRT and was a strong and independent predictor for short disease-specific survival (DSS) of ESCC patients. Furthermore, the therapeutic sensitivity of CRT was substantially increased by ectopic overexpression of DAB2IP in ESCC cells. In addition, knockdown of DAB2IP dramatically enhanced resistance to CRT in ESCC. Finally, we demonstrated that DAB2IP regulates ESCC cell radiosensitivity through enhancing ionizing radiation (IR)-induced activation of the ASK1-JNK signaling pathway.

CONCLUSIONS:

Our data highlight the molecular etiology and clinical significance of DAB2IP in ESCC, which may represent a new therapeutic strategy to improve therapy and survival for ESCC patients.

• Authors: Zhuting Tong, Weiyang Fang, Meng Xu, YeYe Xia, Rui Wang, Yue Li, Tianqi Zha, Liang Xiao, Shuhao Pan, Huiping Chai, Lei Zhao, Hao Wang, Huaguang Pan, Xiangcun Chen
• Journal: Cancer cell international (Cancer Cell Int) Vol. 22 Issue 1 Pg. 106 (Mar 05 2022) ISSN: 1475-2867 [Print] England
• PMID: 35248066 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).